Read more

June 07, 2023
1 min read
Save

Top in endocrinology: Compounded semaglutide advisory; benefits of afternoon exercise

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA recently released a safety notice directing the public to avoid using compounded salt formulations of semaglutide.

According to the notice, the FDA has received reports of adverse events from patients using compounded semaglutide (Ozempic/Wegovy, Novo Nordisk). Salt forms of the agent, including semaglutide sodium and semaglutide acetate, are different formulations than those used in the FDA-approved drugs and therefore may violate the Federal Food, Drug and Cosmetic Act requirements. It was the top story in endocrinology last week.

FDA HQ in Washington
The FDA recently released a safety notice directing the public to avoid using compounded salt formulations of semaglutide. Image: Adobe Stock

Another top story covered study results that found afternoon exercise was linked to a greater reduction in HbA1c among adults with obesity plus type 2 diabetes than exercise during other times of the day.

Read these and more top stories in endocrinology below:

FDA cautions public, providers to avoid use of compounded salt forms of semaglutide

The FDA is advising people using semaglutide to avoid some compounded formulations due to the use of ingredients that may cause adverse events, according to a safety notice. Read more.

Afternoon exercise linked to greatest HbA1c reduction in type 2 diabetes

Physical activity performed in the afternoon could yield a greater reduction in HbA1c than physical activity during other times in the day, according to an analysis of data from the Look AHEAD trial published in Diabetes Care. Read more.

Semaglutide linked to significant weight loss in adults with obesity in real-world study

Adults with overweight or obesity receiving semaglutide lost 13.4% of their body weight at 1 year, according to findings from a real-world study presented at the European Congress on Obesity. Read more.

Prevalence of autoimmune thyroid disease twice as high among adults with COVID-19

Adults hospitalized with COVID-19 were more likely to test positive for thyroid peroxidase antibodies about 3 months after infection than those who did not have COVID-19, according to study findings from researchers in Italy. Read more.

VIDEO: Pituitary and adrenal research highlights from ECE 23

In this video exclusive, Maria Fleseriu, MD, FACE, reviews the pituitary and adrenal research highlights presented at ECE 2023, the annual meeting of the European Society of Endocrinology, which took place in Istanbul, Turkey, in May. Watch video.